ERBB2 and breast carcinoma: A study that combined treatment of bortezomib and Lapatinib, an inhibitor of epidermal growth factor receptor (EGFR) and HER2 tyrosine kinases, showed a synergistic effect in HER2-overexpressing breast cancer cells [41].